A detailed history of Barclays PLC transactions in Ac Immune Sa stock. As of the latest transaction made, Barclays PLC holds 490 shares of ACIU stock, worth $1,739. This represents 0.0% of its overall portfolio holdings.

Number of Shares
490
Holding current value
$1,739
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$2.99 - $4.2 $1,465 - $2,058
490 New
490 $2,000
Q4 2021

Feb 14, 2022

SELL
$4.83 - $7.56 $34,138 - $53,434
-7,068 Closed
0 $0
Q3 2021

Nov 09, 2021

BUY
$6.2 - $8.34 $43,090 - $57,963
6,950 Added 5889.83%
7,068 $48,000
Q2 2021

Aug 13, 2021

SELL
$6.04 - $8.37 $1,654 - $2,293
-274 Reduced 69.9%
118 $1,000
Q1 2021

May 13, 2021

BUY
$5.32 - $8.96 $1,521 - $2,562
286 Added 269.81%
392 $3,000
Q2 2020

Aug 12, 2020

BUY
$6.57 - $8.3 $696 - $879
106 New
106 $1,000
Q1 2020

May 13, 2020

SELL
$4.24 - $9.89 $568 - $1,325
-134 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$4.56 - $8.78 $1,595 - $3,073
-350 Reduced 72.31%
134 $1,000
Q2 2019

Aug 14, 2019

BUY
$4.72 - $5.88 $2,284 - $2,845
484 New
484 $3,000
Q1 2019

May 15, 2019

SELL
$3.65 - $11.68 $23,279 - $74,495
-6,378 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$7.35 - $11.7 $41,204 - $65,590
5,606 Added 726.17%
6,378 $61,000
Q3 2018

Nov 14, 2018

BUY
$7.88 - $16.45 $6,083 - $12,699
772 New
772 $6,000
Q2 2018

Aug 14, 2018

SELL
$8.17 - $10.9 $44,935 - $59,950
-5,500 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$10.34 - $13.78 $48,598 - $64,766
-4,700 Reduced 46.08%
5,500 $57,000
Q4 2017

Feb 14, 2018

BUY
$10.37 - $12.85 $105,773 - $131,070
10,200
10,200 $131,000

Others Institutions Holding ACIU

About AC Immune SA


  • Ticker ACIU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,413,504
  • Market Cap $296M
  • Description
  • AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...
More about ACIU
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.